Gossamer Bio, Inc. (GOSS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 40M 80M 120M FY22: 0 FY23: 0 FY24: 114.7M FY25: 48.5M FY22 FY23 FY24 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-240M -160M -80M 0 80M 160M 240M FY17: -6.7M FY18: -149M FY19: -186.1M FY20: -234M FY21: -216.1M FY22: -218.6M FY23: -183.8M FY24: -59.9M FY25: -170.7M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-270M -180M -90M 0 90M 180M 270M FY17: -6.8M FY18: -147M FY19: -180.3M FY20: -243.4M FY21: -234M FY22: -229.4M FY23: -179.8M FY24: -56.5M FY25: -170.4M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-210M -140M -70M 0 70M 140M 210M FY17: -5.7M FY18: -51M FY19: -144.8M FY20: -176.4M FY21: -188.9M FY22: -187M FY23: -159.2M FY24: -3.5M FY25: -171.3M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-210M -140M -70M 0 70M 140M 210M FY18: -54.5M FY19: -147.8M FY20: -177.9M FY21: -190.4M FY22: -187.4M FY23: -159.2M FY24: -3.5M FY25: -171.3M FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 80M 160M 240M FY19: 54.7M FY20: 68.5M FY21: 74.8M FY22: 84.6M FY23: 152.6M FY24: 226.2M FY25: 228.5M FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q4 '18: -22.75 Q1 '19: -19.16 Q2 '19: -14.25 Q3 '19: -7.36 Q4 '19: -3.33 Q1 '20: -3.30 Q2 '20: -3.56 Q3 '20: -3.56 Q4 '20: -3.55 Q1 '21: -3.46 Q2 '21: -3.26 Q3 '21: -3.26 Q4 '21: -3.13 Q1 '22: -3.11 Q2 '22: -3.05 Q3 '22: -2.90 Q4 '22: -2.72 Q1 '23: -2.48 Q2 '23: -2.19 Q3 '23: -1.75 Q4 '23: -1.33 Q1 '24: -1.00 Q2 '24: -0.33 Q3 '24: -0.26 Q4 '24: -0.26 Q1 '25: -0.23 Q2 '25: -0.62 Q3 '25: -0.69 Q4 '25: -0.75 Q1 '26: -0.79 Q2 '26: -0.70 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.